Bristol Myers Squibb has signed a major deal with China’s largest pharmaceutical company, Hengrui Medicine. Valued at up to $15.2 billion, this agreement focuses on early-stage drug programs across cancer, blood disorders, and immune diseases. The timing coincides with looming patent expirations that threaten revenue streams for big pharma firms worldwide.

Why the Deal Matters

The agreement involves Bristol Myers paying Hengrui an initial $950 million in structured payments, with the rest tied to development milestones. Bristol will gain exclusive rights to several of Hengrui’s oncology and hematology drugs outside China, Hong Kong, and Macau. Conversely, Hengrui will get rights to some immunology assets within those territories. Additionally, both companies will collaborate on discovering new drugs using Hengrui’s technology.

This deal highlights a shift in the pharmaceutical landscape. Big pharma companies are increasingly licensing from Chinese firms rather than developing everything in-house. Hengrui, which is not a typical generic manufacturer, is a top contender with a pipeline of over 90 therapies and a robust research budget. Its market value is around $54.6 billion, and it’s rapidly expanding its global presence.

Industry Context and the Patent Cliff

The pharmaceutical industry faces a wave of patent expirations worth more than $300 billion between 2025 and 2030. Major drugs like Merck’s Keytruda and Pfizer’s upcoming obesity treatments will soon face generic competition. This creates a scramble for new, patent-protected molecules that can replace lost revenue.

Many companies are turning to licensing deals to fill their pipelines. In 2025, Chinese biotech firms accounted for about a third of all global licensing spending, a sharp rise from just a few years earlier. The average upfront payments for these deals have also increased significantly, showing that Chinese companies now value their innovations more than ever.

Implications for the Future of Pharma

The deal with Hengrui is part of a broader trend where Chinese companies are becoming key players in global drug development. They are not just producing generics but creating innovative therapies that attract international licensing. This shift is fueled by China’s heavy investment in R&D and a strategic focus on high-value biotech sectors.

Meanwhile, Western companies look to Chinese firms for new molecules that can help them remain competitive as their own blockbuster drugs face patent cliffs. The dynamic also reflects a changing balance of power in global biotech and pharma, with China emerging as a major hub for innovation and research.

Overall, this deal shows how industry players are adapting to a new era where collaboration across borders is essential. Chinese biotech firms like Hengrui are proving they can compete on the world stage, offering valuable assets to companies seeking to sustain growth amid patent expirations. It’s a sign of a more interconnected and competitive future for global pharma.

Inspired by

• https://thenextweb.com/news/bms-hengrui-china-pharma-patent-cliff

Sources

• scmp.com